KLOW Blend
A compounded four-peptide clinic blend (KPV + GHK-Cu + BPC-157 + TB-500) built for skin, hair, collagen, and tissue recovery in a single injection.
KLOW is a compounded blend that combines four peptides with complementary mechanisms into one lyophilized vial: KPV (anti-inflammatory), GHK-Cu (collagen and skin), BPC-157 (localized tissue and GI healing), and TB-500 (cell migration and tissue remodeling). It emerged from peptide-clinic culture in the early 2020s as an extension of the 'Wolverine' recovery stack, adding cosmetic and anti-inflammatory layers. Each component is reasonably well characterized on its own, but the blend itself has no controlled clinical trials, no standardized formulation, and no FDA approval at any level.
Class
Compounded multi-peptide blend (KPV + GHK-Cu + BPC-157 + TB-500)
Half-life
Varies by component
Routes
Subcutaneous injection
Category
Healing & Recovery
Researched benefits
What it's studied for
Multi-pathway tissue recovery
Bundles four distinct mechanisms into one injection: anti-inflammatory signaling (KPV), collagen and skin remodeling (GHK-Cu), localized cytoprotection and tendon repair (BPC-157), and actin-driven cell migration (TB-500). The multi-pathway claim is mechanistically true, though additive-versus-synergistic effect is unproven.
Skin quality and collagen support
GHK-Cu is the dominant component by weight and drives collagen synthesis and skin/tissue remodeling; users report skin quality changes within weeks. This effect extrapolates from single-component GHK-Cu data rather than blend trials.
Hair density (with microneedling)
Users report hair density improvements, most consistently when the blend is paired with scalp microneedling. Evidence is anecdotal and subject to strong survivorship bias.
Post-surgical and soft-tissue recovery
BPC-157 contributes localized wound and tendon healing while TB-500 supports broader tissue remodeling via actin regulation; the pair underlies frequently reported post-surgery recovery outcomes.
Gut and immune modulation
KPV, an anti-inflammatory tripeptide derived from alpha-MSH, has preclinical data on intestinal inflammation and antimicrobial activity; users with pre-existing GI issues report improved gut comfort. Human efficacy data for KPV is limited.
Convenience of a single injection
The main practical advantage is delivering four complementary peptides in one vial and one injection rather than four separate reconstitutions and shots. Much of KLOW's appeal is convenience rather than demonstrated synergy over the parts.
Mechanism
How it works
KLOW is not a single molecule but a compounded combination of four peptides, each acting through its own established pathway. KPV is an anti-inflammatory tripeptide (Lys-Pro-Val) derived from the C-terminus of alpha-MSH; it modulates gut inflammation and systemic immune responses and shows antimicrobial signaling in preclinical models. GHK-Cu, the copper tripeptide, is the dominant component by weight and stimulates collagen synthesis and skin/tissue remodeling.
BPC-157 provides localized cytoprotection, supporting wound healing, tendon repair, and gastrointestinal protection with anti-inflammatory effects. TB-500 is an actin-binding fragment associated with thymosin beta-4 that drives cell migration and broader tissue remodeling. Together the four are marketed as covering anti-inflammatory, cosmetic/collagen, localized-healing, and systemic-repair axes simultaneously.
A practical nuance concerns the TB-500 line item: the name TB-500 denotes the ~889 Da Ac-LKKTETQ fragment, but third-party KLOW certificates of analysis routinely list full-length thymosin beta-4 (~4963 Da) under the same name. The measured mass on the COA is what actually indicates which molecule is present in a given vial.
Critically, KLOW is a clinic practice pattern assembled from better-known parts rather than a validated fixed-dose drug. The multi-pathway rationale is mechanistically coherent, but whether the combination produces synergy beyond the simple sum of its components has never been formally tested, and no controlled trial exists on the blend itself.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
KLOW ships as a single lyophilized vial (typically ~80 mg total loading, GHK-Cu dominant at ~50 mg) reconstituted with bacteriostatic water per the compounding source's instructions. Because component ratios vary across vendors, the specific reconstitution volume and resulting per-unit dose depend entirely on the individual vial's labeling and COA.
Compounded clinic use
- Dose
- Per compounding-pharmacy or clinic protocol (no standardized dose exists)
- Frequency
- Typically daily during an active recovery block
- Timing
- As directed by the prescribing protocol
- Duration
- Commonly sold as a monthly package
- Route
- Subcutaneous injection
KLOW has no FDA approval and no controlled clinical dosing data. Formulations and component ratios vary by source, so dose is dictated by the specific vial's label and certificate of analysis rather than a validated regimen.
- No validated beginner/intermediate/advanced protocol exists for the blend; all dosing is extrapolated from single-component practice or set by the compounding source.
- Compounding consistency is a real practical issue: ratios and total loadings (reported around 70-80 mg total) vary between compounding pharmacies and research-peptide vendors.
- Verify the certificate of analysis, particularly to confirm whether the 'TB-500' component is the ~889 Da fragment or full-length thymosin beta-4 (~4963 Da).
- Clinic use is not equivalent to a validated protocol, and the combined long-term safety profile of the blend has not been formally characterized.
Combinations
Stacking & blends
KLOW as an all-in-one recovery stack
Broad-spectrum tissue recovery, skin quality, and anti-inflammatory coverage in a single injection
The blend is itself a fixed stack of four complementary peptides, extending the BPC-157 + TB-500 'Wolverine' recovery pairing with GHK-Cu for collagen/skin and KPV for anti-inflammatory and gut/immune support.
KLOW plus scalp microneedling
Hair density and scalp/skin improvement
Users most consistently report hair density gains when KLOW is paired with scalp microneedling, leveraging GHK-Cu's collagen and skin-remodeling activity alongside enhanced local delivery.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy or breastfeeding
- Known hypersensitivity to any component peptide
Reported side effects are generally clean, reflecting the mild profiles of the individual components, with occasional injection-site soreness the most common complaint. Because the blend has no clinical trial data, its combined long-term safety profile is uncharacterized, and combining four peptides may additively increase the probability of any individual component's side effects.
FAQ
KLOW Blend — common questions
What is KLOW?
KLOW is a compounded peptide blend containing four peptides in a single vial: KPV (an anti-inflammatory tripeptide), GHK-Cu (a copper peptide for skin and tissue), BPC-157 (a wound-healing peptide), and TB-500. It is marketed by peptide clinics as a broad-spectrum healing and aesthetic protocol.
What does KLOW do?
It combines four complementary mechanisms: KPV modulates gut inflammation and immune response, GHK-Cu stimulates collagen synthesis and skin remodeling, BPC-157 supports localized wound healing, and TB-500 drives systemic tissue repair via actin regulation. It is positioned as a combined recovery and aesthetic protocol.
Does the blend actually work better than the parts?
The pharmacology of each component holds up on its own, but the blend itself has zero controlled trials. Every clinical claim extrapolates from single-component data, and synergy versus simple addition has never been formally tested. The honest read is that the parts are better evidenced than the sum, and the sum may just be the parts plus the convenience of one injection.
How is KLOW dosed?
There is no FDA approval and no controlled clinical dosing data. Formulations vary by source, so the dose depends on the specific vial's labeling and certificate of analysis. Clinic use is not the same as a validated protocol.
What is the 'TB-500' caveat in KLOW?
The name TB-500 technically denotes the ~889 Da Ac-LKKTETQ fragment, but third-party KLOW certificates of analysis routinely list full-length thymosin beta-4 (~4963 Da) under that name. The measured mass on the COA is what tells you which molecule is actually in the vial.
Is KLOW FDA approved?
No. KLOW is a compounded peptide blend, and none of its component peptides are FDA-approved for the indications it is marketed for. In April 2026 the FDA removed BPC-157, TB-500, KPV, and injectable GHK-Cu from the 503A category-2 compounding list, with PCAC review pending.
What are the side effects of KLOW?
Reports are generally clean, reflecting the mild profiles of the individual components, with occasional injection-site soreness the most common effect. Because the blend has no clinical trial data, its combined long-term safety profile has not been formally characterized.
